MTNB News Alert Matinas Biopharma Hl (MTNB) 0.4600 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Matinas Biopharma Hl (MTNB) 0.4600 $MTNB

Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
PR Newswire - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 2.84 (-0.06), ONVO: 6.29 (-0.24), CYTX: 0.47 (-0.04), IAG: 2.21 (-0.12)

Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
GlobeNewswire - Mon Nov 24, 6:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that it has appointed Kevin C. Maki, Ph.D. to its recently formed Scientific Advisory Board (SAB).

Matinas BioPharma to Present at Two Investor Conferences in Early December
GlobeNewswire - Thu Nov 20, 9:12AM CST
- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST -

Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
GlobeNewswire - Wed Nov 12, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has commenced dosing in the first-in-human study of MAT9001. The Company's initial trial is being conducted in Canada and is a pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 versus an active comparator.

Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001
GlobeNewswire - Mon Nov 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent Application Serial No. 14/101,165 entitled, "Methods of Administering Compositions Comprising Docosapentaenoic Acid." Upon issuance, the patent will provide intellectual property protection through 2033.

Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
GlobeNewswire - Tue Nov 04, 6:39AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has established a new Scientific Advisory Board (SAB) and appointed internationally renowned cardiologist Christie M. Ballantyne, M.D., as its first SAB member. The Company expects to add additional SAB members over the coming months.

Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
GlobeNewswire - Wed Oct 29, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has received a Notice of Authorization from Health Canada to initiate the first-in-human study of MAT9001. The Company expects to commence dosing in this pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 in Canada during the fourth quarter of 2014 and report topline data in the second quarter of 2015.

Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has submitted an Investigational New Drug application (IND) for MAT9001 to the United States Food and Drug Administration (FDA).

Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014
GlobeNewswire - Tue Sep 30, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that Roelof Rongen, President and Chief Executive Officer, will be presenting at the 13th Annual BIO Investor Forum being held October 7-8, 2014 at the Palace Hotel in San Francisco, California. The annual BIO Investor Forum is hosted by the Biotechnology Industry Organization (BIO) and features leading private and emerging public companies.

Matinas BioPharma - "Clinical Treatment Guidelines for Dyslipidemia Continue to Evolve"
ACCESSWIRE - Mon Sep 29, 9:30AM CDT
New York, NY / September 29, 2014 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

SeeThruEquity Announces Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 4:27PM CDT
Conference Being Held at Convene Times Square in Midtown

SeeThruEquity Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 8:13AM CDT
Conference Being Held at Convene Times Square in Midtown

Matinas BioPharma Holdings, Inc. Approved to Trade on OTCQB Venture Stage Marketplace
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has been approved to continue quotation of its securities on OTCQB, the venture stage marketplace (the "OTCQB" , effective as of September 5, 2014. The Company's shares will continue to trade under the ticker symbol "MTNB."

Matinas BioPharma to Present at Three Investor Conferences in September
GlobeNewswire - Thu Sep 04, 6:05AM CDT
- Rodman & Renshaw 16 Annual Global Investment Presentation and Live Audio Webcast on September 9, 2014 -

S&P Capital IQ Initiates Coverage on Matinas BioPharma Holdings, Inc. in S&P Capital IQ Factual Stock Reports
PR Newswire - Wed Sep 03, 8:38AM CDT
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on Matinas BioPharma Holdings, Inc.
MHFI: 86.56 (-1.43)

SeeThruEquity Initiates Research Coverage on Matinas BioPharma Holdings, Inc. with Target Price of $3.78
ACCESSWIRE - Wed Sep 03, 8:09AM CDT
New York, NY / ACCESSWIRE / September 3, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Matinas BioPharma Holdings, Inc. (OTCBB: MTNB), a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic diseases.
GSK: 41.92 (+0.62)

Matinas BioPharma - "Lipidomics - An Exciting Foundation for Matinas BioPharma"
ACCESSWIRE - Wed Aug 06, 8:28AM CDT
New York, NY / August 6, 2014 / Matinas BioPharma (OTCBB:MTNB) published a new blog post today on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Mr. Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Matinas BioPharma Launches Digital Corporate Communication Channels
GlobeNewswire - Thu Jul 31, 7:09AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCBB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today a suite of online corporate communication channels to maintain on-going and direct communication with shareholders and other interested parties. The Company has launched official digital portals on social medial channels including Facebook, Twitter, LinkedIn, Google+, and The Chairman's Blog.

Matinas BioPharma Holdings, Inc. Common Stock Commences Trading on OTCBB Under Ticker Symbol MTNB
Marketwire - Tue Jul 22, 7:15AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCBB: MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that its shares of common stock have initiated trading via the Over-the-Counter Bulletin Board (OTCBB) under the ticker symbol "MTNB."




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 87

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 272

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 127

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 35

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 87

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 21

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 82

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 56

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 35

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 161

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Mark Uyeda Takes the Lead as Acting SEC Chair Under Trump

Updated Category News Views 131

Mark Uyeda Appointed Acting Chair of the SEC Recently inaugurated President Donald Trump has appointed Mark Uyeda, a Republican member of the U.S. Securities and Exchange Commission (SEC), as the acting chair of the agency. This announcement from the White House marks a significant moment in the leadership of one of the country’s key financial regulatory bodies....

Continue Reading
Diaper Bank Marks Historic Milestone: One Million Diapers Given

Updated Category News Views 146

Diaper Bank Celebrates a Significant Achievement The Diaper Bank of the Inland Empire has proudly reached a wonderful milestone by distributing its one millionth diaper to families in need. This accomplishment underscores the vital role of community support and the ongoing necessity for resources to help families tackle diaper shortages. Dedicated to Community Needs...

Continue Reading
Franklin Electric Boosts Dividend Amid Strong Business Outlook

Updated Category News Views 159

Franklin Electric Announces Increased Quarterly Cash Dividend Franklin Electric Co., Inc. (NASDAQ: FELE) has made headlines with its recent announcement regarding a quarterly cash dividend of $0.265 per share. This decision reflects the company's robust financial health and a solid commitment to delivering value to its shareholders. The upcoming payment, set for February...

Continue Reading
GLS Italy Partners with Quadient to Elevate Parcel Services

Updated Category News Views 461

GLS Italy Enhances Delivery Options with Quadient Partnership GLS is making significant strides in the field of e-commerce delivery innovation by expanding its network of pick-up points. This expansion comes in the wake of a strategic partnership with Quadient, a leader in automation technologies, which introduces smart, carrier-agnostic lockers into the Italian market....

Continue Reading
Understanding Baidu's Unusual Options Trends and Insights

Updated Category News Views 155

Analyzing Baidu's Options Activity Investors and analysts are taking a close look at the unusual options activity surrounding Baidu. Recent patterns suggest that major players in the market are positioning themselves with a bearish outlook, raising interest among traders. Particularly, the volume of activity in the options market for Baidu (NASDAQ: BIDU) signals a notable...

Continue Reading